Compare Orchid Chemicals with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN ORCHID PHARMA LTD/
LUPIN
 
P/E (TTM) x -0.5 106.7 - View Chart
P/BV x 0.1 2.4 4.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   LUPIN
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN
Mar-19
ORCHID PHARMA LTD/
LUPIN
5-Yr Chart
Click to enlarge
High Rs194986 19.7%   
Low Rs35720 4.9%   
Sales per share (Unadj.) Rs276.5369.5 74.8%  
Earnings per share (Unadj.) Rs-79.213.4 -590.9%  
Cash flow per share (Unadj.) Rs-43.537.4 -116.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.9303.7 17.8%  
Shares outstanding (eoy) m70.45452.49 15.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.3 17.9%   
Avg P/E ratio x-1.463.6 -2.3%  
P/CF ratio (eoy) x-2.622.8 -11.5%  
Price / Book Value ratio x2.12.8 75.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,067386,064 2.1%   
No. of employees `0002.817.7 15.8%   
Total wages/salary Rs m2,52731,513 8.0%   
Avg. sales/employee Rs Th6,956.19,453.8 73.6%   
Avg. wages/employee Rs Th902.51,782.0 50.6%   
Avg. net profit/employee Rs Th-1,993.0343.0 -581.0%   
INCOME DATA
Net Sales Rs m19,477167,182 11.7%  
Other income Rs m4073,640 11.2%   
Total revenues Rs m19,884170,822 11.6%   
Gross profit Rs m1,10328,822 3.8%  
Depreciation Rs m2,51910,850 23.2%   
Interest Rs m5,2273,078 169.8%   
Profit before tax Rs m-6,23618,534 -33.6%   
Minority Interest Rs m20-89 -22.1%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m511-3,400 -15.0%   
Tax Rs m-1259,017 -1.4%   
Profit after tax Rs m-5,5806,066 -92.0%  
Gross profit margin %5.717.2 32.8%  
Effective tax rate %2.048.7 4.1%   
Net profit margin %-28.73.6 -789.7%  
BALANCE SHEET DATA
Current assets Rs m11,014138,536 8.0%   
Current liabilities Rs m32,06061,299 52.3%   
Net working cap to sales %-108.146.2 -233.9%  
Current ratio x0.32.3 15.2%  
Inventory Days Days9584 113.3%  
Debtors Days Days34112 29.8%  
Net fixed assets Rs m29,440127,516 23.1%   
Share capital Rs m705905 77.8%   
"Free" reserves Rs m2,043136,517 1.5%   
Net worth Rs m3,800137,422 2.8%   
Long term debt Rs m9,01866,417 13.6%   
Total assets Rs m46,510279,494 16.6%  
Interest coverage x-0.27.0 -2.8%   
Debt to equity ratio x2.40.5 491.0%  
Sales to assets ratio x0.40.6 70.0%   
Return on assets %-0.83.3 -23.2%  
Return on equity %-146.94.4 -3,327.2%  
Return on capital %-3.78.9 -41.9%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51359,414 12.6%   
Fx outflow Rs m5,64922,282 25.4%   
Net fx Rs m1,86537,132 5.0%   
CASH FLOW
From Operations Rs m1,68216,660 10.1%  
From Investments Rs m-9,860-32,825 30.0%  
From Financial Activity Rs m6,6447,441 89.3%  
Net Cashflow Rs m-1,535-8,724 17.6%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS